Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 15NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Melanoma 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Neoplasms 6Lymphoma, Non-Hodgkin 6Carcinoma, Non-Small-Cell Lung 6Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Merkel Cell 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Neoplasm Metastasis 3Multiple Myeloma 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Small Cell Lung Carcinoma 2Skin Neoplasms 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2

Interventions

Cytarabine 21Imatinib Mesylate 20venetoclax 16Azacitidine 16nilotinib 15Cyclophosphamide 15fludarabine 13Dasatinib 12blinatumomab 10Rituximab 10quizartinib 7Gemtuzumab 7Daunorubicin 7ruxolitinib 6Drug Therapy 6Clofarabine 6Bendamustine Hydrochloride 6AP 1903 reagent 6ponatinib 5fludarabine phosphate 5Whole-Body Irradiation 5Vincristine 5Mycophenolic Acid 5Methotrexate 5Granulocyte Colony-Stimulating Factor 5Dexamethasone 5vosaroxin 4revumenib 4rasburicase 4forodesine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia × Interleukin-2 × Clear all
NCT04629729 2026-03-19

FT819 in Subjects With B-cell Malignancies

Fate Therapeutics

Phase 1 Active not recruiting
54 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡